Due to its role as a chemokine that promotes EMT of tumor cells, the recruitment of MDSCs to tumor site, subsequent immune escape, and its frequent overexpression in malignancies, including TNBC, IL-8 has been evaluated as a therapeutic target. This evidence concerns the gene CXCL8 and neoplasm.